Heparin Cofactor II: Discovery, Properties, and Role in Controlling Vascular Homeostasis
Authors:
- Jennifer W MitchellJMJennifer W Mitchell
- Yolanda M FortenberryYFYolanda M Fortenberry
- Frank C ChurchFCFrank C Church
- 1 June 2011
- journal article
- research article
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 37 (04) , 339-348
Abstract
Heparin cofactor II (HCII) is a serine protease inhibitor (serpin) found in high concentrations in human plasma. Despite its discovery >30 years ago, its physiological function is still poorly understood. It is known to inhibit thrombin, the predominant coagulation protease, and HCII-thrombin complexes have been found in plasma, yet it is thought to contribute little to normal hemostasis. However, thrombin has several other physiological functions, and therefore many biological roles for HCII need consideration. The unique structure and mechanism of action of HCII have helped guide our understanding of HCII. In particular, HCII binds many glycosaminoglycans (GAGs) such as heparin and heparin sulfate as well as several different polyanions to enhance its inhibition of thrombin. Distinctly, HCII is able to use the GAG dermatan sulfate for accelerated thrombin inhibition. Dermatan sulfate is found in high concentrations in the walls of blood vessels as well as in placental tissue. This knowledge has led to research indicating that HCII may play a protective role in atherosclerosis and placental thrombosis. Additionally, pharmaceuticals are being developed that use the dermatan sulfate activation of HCII for anticoagulation. Although much research is still needed to fully understand HCII, this humble protein may have significant impact in our medical future. This article reviews the laboratory history, protein characteristics, structure–activity relationships, protease inhibition, physiological function, and medical relevance of HCII in hopes of regenerating interest in this sometimes forgotten serpin.Keywords
This publication has 69 references indexed in Scilit:
- Higher specificity of the activity of low molecular weight fucoidan for thrombin-induced platelet aggregationThrombosis Research, 2010
- Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) studyExperimental and Molecular Pathology, 2009
- Anticoagulant activity of a sulfated polysaccharide from the green alga Arthrospira platensisBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Oversulfated chondroitin sulfate interaction with heparin-binding proteins: New insights into adverse reactions from contaminated heparinsBiochemical Pharmacology, 2009
- Sulfonation of papain-treated chitosan and its mechanism for anticoagulant activityCarbohydrate Research, 2009
- Heparin cofactor II–thrombin complex: A biomarker of MPS diseaseMolecular Genetics and Metabolism, 2008
- Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular eventsInternational Journal of Cardiology, 2007
- Heparin cofactor II–thrombin complex in MPS I: A biomarker of MPS diseaseMolecular Genetics and Metabolism, 2006
- Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: Implications for a possible physiological function of heparin cofactor IIBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Heparin cofactor II is more sensitive than antithrombin to secretory impairment arising from mutations introduced into its carboxy-terminal regionThrombosis Research, 2004